Early use of J&J’s Zytiga extends prostate cancer survival

http://ift.tt/1jUfBeX

Adding Johnson & Johnson’s Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results. The data, which supports expanding the drug’s use to earlier stages of prostate cancer, is “likely to change clinical practice overnight,” said Dr Richard Shilsky, chief medical officer at the American Society of Clinical Oncology, which featured the studies on Saturday at its annual meeting in Chicago. J&J is already seeking European Union approval in the earlier treatment setting, but is still considering whether to pursue U.S. approval.

June 04, 2017 at 09:01PM

http://ift.tt/2qUpOip

from

http://ift.tt/2qUpOip